GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Telo Genomics Corp (OTCPK:TDSGF) » Definitions » Debt-to-Equity

TDSGF (Telo Genomics) Debt-to-Equity : 0.00 (As of Dec. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Telo Genomics Debt-to-Equity?

Telo Genomics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was $0.00 Mil. Telo Genomics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was $0.00 Mil. Telo Genomics's Total Stockholders Equity for the quarter that ended in Dec. 2024 was $1.23 Mil. Telo Genomics's debt to equity for the quarter that ended in Dec. 2024 was 0.00.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Telo Genomics's Debt-to-Equity or its related term are showing as below:

During the past 13 years, the highest Debt-to-Equity Ratio of Telo Genomics was 0.06. The lowest was -0.53. And the median was 0.01.

TDSGF's Debt-to-Equity is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 0.23
* Ranked among companies with meaningful Debt-to-Equity only.

Telo Genomics Debt-to-Equity Historical Data

The historical data trend for Telo Genomics's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Telo Genomics Debt-to-Equity Chart

Telo Genomics Annual Data
Trend Dec14 Dec15 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.05 0.01 0.02 0.01 -

Telo Genomics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.03 - - - -

Competitive Comparison of Telo Genomics's Debt-to-Equity

For the Diagnostics & Research subindustry, Telo Genomics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Telo Genomics's Debt-to-Equity Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Telo Genomics's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Telo Genomics's Debt-to-Equity falls into.


;
;

Telo Genomics Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Telo Genomics's Debt to Equity Ratio for the fiscal year that ended in Jun. 2024 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0 + 0) / 0.43
=0.00

Telo Genomics's Debt to Equity Ratio for the quarter that ended in Dec. 2024 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0 + 0) / 1.228
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Telo Genomics  (OTCPK:TDSGF) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Telo Genomics Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Telo Genomics's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Telo Genomics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Telo Genomics Corp (OTCPK:TDSGF) » Definitions » Debt-to-Equity
Comparable Companies
TSXV:ARC TSXV:AVCR XCNQ:IZO XCNQ:BUX XCNQ:VTAL TSXV:MBI.H XCNQ:SONA TMO DHR XSWX:LONN IDXX A IQV SHSE:603259 MTD WAT NTRA LH DGX XPAR:BIM
Traded in Other Exchanges
TELO:Canada
Address
101 College Street, Suite 200, MaRS Centre, South Tower, Toronto, ON, CAN, M5G 1L7
Website
https://www.telodx.com
Telo Genomics Corp is a personalized medicine company. The company through its wholly-owned subsidiary is engaged in developing diagnostic and prognostic products that may save lives, improve the quality of life, and reduce the cost of care associated with numerous diseases that display genomic instability. The company has a single operating segment, focused on the development and commercialization of predictive technological products designed to personalize treatment plans for patients who have specific conditions.